Insider · CIK 0001247024

KAPLAN GILLA

Reports to the SEC for 4 companies · WAYNE, PA

sec.gov

Transactions

Companies

Filings

CIK

0001247024

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-02	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.1K sh	—	—	20,100
2026-03-28	AVTXAvalo Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,166 sh	—	—	3,167
2026-03-28	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,166 sh	—	—	6,333
2026-03-26	TYRATyra Biosciences, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−53.2K sh	$37.75	−$2.01M	28,231
2026-03-26	TYRATyra Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−53.2K sh	—	—	0
2026-03-26	TYRATyra Biosciences, Inc.M Exercise/Conversion	Director	MExercise/Conversion	−53.2K sh	$2.25	−$120K	81,403
2026-03-25	TYRATyra Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−14.3K sh	—	—	53,172
2026-03-25	TYRATyra Biosciences, Inc.S Sale	Director	SSale	−14.3K sh	$36.97	−$529K	28,231
2026-03-25	TYRATyra Biosciences, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+14.3K sh	$2.25	+$32.2K	42,526
2025-06-18	TYRATyra Biosciences, Inc.S Sale	Director	SSale	−9,568 sh	$9.78	−$93.6K	28,231
2025-06-17	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.1K sh	—	—	20,100
2025-06-17	TYRATyra Biosciences, Inc.S Sale	Director	SSale	−10 sh	$10.35	−$103.5	37,799
2025-06-16	TYRATyra Biosciences, Inc.S Sale	Director	SSale	−6,814 sh	$10.38	−$70.7K	37,809
2025-06-13	TYRATyra Biosciences, Inc.S Sale	Director	SSale	−15K sh	$10.31	−$155K	44,623
2025-06-12	TYRATyra Biosciences, Inc.S Sale	Director	SSale	−30K sh	$10.31	−$309K	59,623
2025-05-29	TYRATyra Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.2K sh	—	—	22,200
2025-03-28	AVTXAvalo Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,167 sh	—	—	3,167
2025-03-28	AVTXAvalo Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,167 sh	—	—	6,333
2024-08-13	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+24.6K sh	—	—	24,600
2024-08-13	AVTXAvalo Therapeutics, Inc. · Restricted Stock UnitsA Award	Director	AAward	+9,500 sh	—	—	9,500
2024-06-13	TYRATyra Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−61.4K sh	—	—	0
2024-06-13	TYRATyra Biosciences, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+61.4K sh	$0.61	+$37.4K	89,623
2024-05-29	TYRATyra Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.6K sh	—	—	18,600
2023-12-20	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+3,334 sh	—	—	3,334
2023-05-31	TYRATyra Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.5K sh	—	—	14,500
2022-09-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+3,080 sh	—	—	3,080
2022-06-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+44.1K sh	—	—	44,115
2022-06-14	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2022-06-13	TYRATyra Biosciences, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.5K sh	—	—	14,500
2022-03-31	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30.4K sh	—	—	30,359
2021-12-31	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+12.8K sh	—	—	12,767
2021-09-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+9,541 sh	—	—	9,541
2021-06-30	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+6,353 sh	—	—	6,353
2021-06-15	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2021-03-31	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+7,650 sh	—	—	7,650
2020-12-31	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+7,216 sh	—	—	7,216
2020-10-08	AVTXAvalo Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+50K sh	—	—	50,000
2018-05-18	CELGENE CORP /DE/Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−27.8K sh	—	—	0
2018-05-18	CELGENE CORP /DE/S Sale	Director	SSale	−27.8K sh	$78.66	−$2.18M	76,301
2018-05-18	CELGENE CORP /DE/M Exercise/Conversion	Director	MExercise/Conversion	+27.8K sh	$30.01	+$833K	104,051
2018-02-20	CELGENE CORP /DE/S Sale	Director	SSale	−9,250 sh	$94.83	−$877K	76,301
2018-02-15	CELGENE CORP /DE/Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,250 sh	—	—	0
2018-02-15	CELGENE CORP /DE/S Sale	Director	SSale	−9,250 sh	$95.99	−$888K	85,551
2018-02-15	CELGENE CORP /DE/M Exercise/Conversion	Director	MExercise/Conversion	+9,250 sh	$27.18	+$251K	94,801
2017-12-05	CELGENE CORP /DE/M Exercise/Conversion	Director	MExercise/Conversion	+9,250 sh	$24.96	+$231K	85,551
2017-12-05	CELGENE CORP /DE/Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,250 sh	—	—	0
2017-09-12	CELGENE CORP /DE/Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,250 sh	—	—	0
2017-09-12	CELGENE CORP /DE/S Sale	Director	SSale	−9,250 sh	$141.56	−$1.31M	76,301
2017-09-12	CELGENE CORP /DE/M Exercise/Conversion	Director	MExercise/Conversion	+9,250 sh	$33.88	+$313K	85,551
2017-08-02	CELGENE CORP /DE/S Sale	Director	SSale	−7,500 sh	$134.52	−$1.01M	76,301

Recent filings

Accepted (ET)
Jun 44
KAPLAN GILLA0001247024-26-000004
SEC(opens sec.gov)
Mar 314
KAPLAN GILLA0001247024-26-000002
SEC(opens sec.gov)
Mar 274
KAPLAN GILLA0001193125-26-129239
SEC(opens sec.gov)
Jun 204
KAPLAN GILLA0000950170-25-088602
SEC(opens sec.gov)
Jun 184
KAPLAN GILLA0001578563-25-000322
SEC(opens sec.gov)
Jun 164
KAPLAN GILLA0000950170-25-086960
SEC(opens sec.gov)
Jun 24
KAPLAN GILLA0000950170-25-080226
SEC(opens sec.gov)
Apr 14
KAPLAN GILLA0001578563-25-000200
SEC(opens sec.gov)
Aug 144
KAPLAN GILLA0001578563-24-000365
SEC(opens sec.gov)

Companies

Address

C/O AVALO THERAPEUTICS, INC. 1500 LIBERTY RIDGE DRIVE, SUITE 321

WAYNE, PA, 19087